The findings raise the possibility that drugs recently tested as treatments for fragile X may be ineffective, at least in part,
and cartilage grafts without the need for anti-rejection drugs, and the donor tissue becomes part of the joint.
at the very place where the drugs could be the most effective. This could be a strong model for fighting Parkinson's
#Could cell#backpacks#deliver inflammation drugs? Scientists have created ellular backpacksthat could carry therapeutic agents to the site of inflammation
ASICALLY THE MAIN BENEFIT IS THAT YOU CAN DELIVER THE DRUG IN A MORE EFFECTIVE DOSE However,
we could deliver the drug there, says Mitragotri, who specializes in targeted drug delivery. By taking advantage of natural body processes, researchers at UC Santa barbara and MIT have developed a method of targeting inflamed tissues
creating a way to treat both the inflammation and its underlying cause. t a cell-mediated approach to targeted drug delivery,
says grad student researcher Aaron Anselmo, lead author of a study in the current issue of the Journal of Controlled Release.
Further studies will include research into how much drug can be loaded into the cellular backpacks. Ideally, Anselmo says,
the cellular backpacks loaded with drugs would be injected into the bloodstream, whereupon they would attach to these traveling monocytes
and release their drugs.""It is a good idea to get your levels checked on a yearly basis
. If you are deficient, you and your doctor can make a plan on how to reverse it through diet, supplements,
say the researchers. asically the main benefit is that you can deliver the drug in a more effective dose,
but it could also allow for higher doses of drug to the site, which could decrease treatment time h
We think that this new approach could ultimately form the basis for future superconducting electronics says Jespersen.
#Shire Acquires NPS Pharma for $5. 2b Shire will acquire NPS Pharmaceuticals for about $5. 2 billion cash,
The drug PDUFA target date for a decision is January 24. That date was delayed three months in October,
NPSSINGLE marketed drug is Gattex (teduglutide rdna origin), an injection drug indicated for long-term treatment of adults with short bowel syndrome (SBS) who need parenteral support.
would complement Shire existing stable of drugs for gastrointestinal diseases.""The acquisition of NPS Pharma is a significant step in advancing Shire's strategy to become a leading biotechnology company, Shire CEO Flemming Ornskov, M d,
Janssen Pharmaceuticals markets tapentadol as Nucynta in the U s.;and Kyowa hakko Kirin markets cinacalcet HCI as Regpara in Japan, Hong kong, Malaysia, Macau, Singapore, and Taiwan.
"This makes drug screening much easier, faster and less expensive than using a mouse model, for instance,
Drugs that successfully block its action have been developed, but these drugs have to be administered for long periods of time to successfully trigger cell death and shrink tumors,
leading to considerable toxicities. This outcome is partially because cells in any one tumor have chromosomes with different telomere lengths
Since more than half of patients suffering from major depression disorder (MDD) do not respond to antidepressant treatment,
#Whole-Exome Sequencing Technology Identifies Drug Resistance Gene in Testicular cancer A study, funded by the Movember Foundation and conducted by scientists at The Institute of Cancer Research (ICR) in London,
in addition to uncovering a gene that may aid tumors in promoting resistance to existing drug therapies.
about 3%of patients develop resistance to platinum-based drugs, which consequently is associated with a diminished long-term survival rate.
as J&j has done with pharmaceutical clinical trial data since last year. Under the agreement, the YODA Project will approve
or deny requests from investigators for de-identified patient data associated with the pharmaceutical, medical device,
as Johnson & johnson leadership in this area now extends from sharing its drug data to sharing its device
Eleven drug developers have committed to sharing clinical trial data through clinicalstudydatarequest. com and allow an independent review panel to decide data requests:
Astellas, Bayer, Boehringer ingelheim, Glaxosmithkline, Lilly, Novartis, Roche, Sanofi, Takeda, UCB, and Viiv Healthcare. Three industry groupspharmaceutical Research and Manufacturers of America (Phrma), the European Federation of Pharmaceutical industries and Associations (EFPIA),
but not the open-access sought by Europe chief drug regulator and Glaxosmithkline. The European Medicines Agency in October issued a more expansive data sharing policy last October,
whose data led to approval of Astrazeneca Brilinta (ticagrelor). Questions about geographic discrepancies of outcomes, study-site monitoring,
including live cells and drugs, according to the researchers. Thousands of times thinner than the average human hair, nanofibers are used by medical researchers to create advanced wound dressings and for tissue regeneration
drug testing, stem cell therapies, and the delivery of drugs directly to the site of infection."
"The process we have developed makes it possible for almost anyone to manufacture high-quality nanofibers without the need for expensive equipment,
Zaltrap developer Sanofi responded with 50%discounts while maintaining its official price. A year later, some 120 investigators and other experts in chronic myeloid leukemia (CML) publicly demanded lower cancer drug prices.
and officials to negotiate drug prices with developers. Now years of talk is finally translating into action on bringing down the price of cancer drugs.
Express Scripts, a pharmacy benefit manager that processed some 1. 3 billion U s. prescriptions last year,
The payer won say which drugs or companies are the subject of discussions, first reported last month by The Wall street journal. Brian Henry, Express Scriptsvp,
Cancer was the third most expensive category of specialty drugs last year measured per-member-per year, according to Express Scripts;
and is among a handful of key drivers of rising costs here are drugs in cancer that may give five months of life in one indication and 12 days of life in another.
Henry said June 3. hen you get to the point where you have orphan drug pricing for non-orphan drugs,
Express Scripts sees similar cost-reduction opportunity for inflammatory and MS drugs, he added. Drug makers have resisted traditionally value-based pricing,
arguing they need to recoup R&d costs. The about-face reflects the convulsive changes wrought by U s. healthcare reform
and Europe embrace of government-led value-based drug pricing. In the U k.,the National Institute for Health and Care Excellence (NICE) makes formulary determinations through a ost-effectivenessthreshold assessing estimated costs of treatments or services in relation to their expected health benefits.
setting reimbursements for new drugs at the same level as the best existing comparator unless the new drugs show superiority to that comparator;
not just important new drugs. Theye also a new idea. I also think it true for Gleevec.
which are the sole buyers of drugs for state-run healthcare systems, numerous U s. payers exist.
Ph d.,research associate professor with the Tufts Center for the Study of Drug Development, told GEN. Having numerous payers,
the U s is less likely to see drug developers offer the extent of free trials or money-back guarantees,
or rebates for new drugs, as many have done in Europe to gain market access. Numerous payers is one reason why prices set by U s. payers will likely be more palatable to drug developers than
as payer cut prices for less-effective treatmentsven after developers invest in IT systems, drug utilization programs,
the company immediately added Abbvie Viekira Pak to its National Preferred Formulary as the exclusive option for patients with genotype 1 hepatitis Cust three days after the FDA approved the drug.
By providing access for a large customer base on its biggest formulary to a single hep C drug and a single pharmacy (Accredo Specialty Pharmacy
Abbvie agreed to an undisclosed lower price for Viekira Pak, which lists at $83, 319 per 12-week course.
Henry said the lower price is consistent with discounts given for the drug in Europe for Sovaldi,
Express Scriptsindependent Pharmacy & Therapeutics Committee concluded that Viekira Pak was at least clinically equivalent to two Gilead sciences drugs, Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir.
and only covers Sovaldi for non-genotype 1 hepatitis C. ur clients will save more than $1 billion this year on hepatitis C medications,
Express Scripts pursued talks with Abbvie after failing to reach agreement with Gilead on a discount for Sovaldi
000-a-pill pricing by noting that the cost of Sovaldi is lower than the cost of complications associated with hepatitis C treatment, such as liver damage or liver failure.
and drug developerss well as pooling and sharing of resources. Institutions, developers, and patient groups should be encouraged to form consortia capable of assembling subpopulations large enough to speed up development,
Cancer treatments marketed by eight companies accounted for six of the Top 25 Best-selling Drugs of 2014 as listed by GEN,
and its Genentech subsidiary from marketing the top three cancer treatments: Rituxan (rituximab, co-marketed with Biogen and ranked#4), Avastin (bevacizumab;#
Genentech spokeswoman Susan Willson told GEN. Roche has based an indication pricing system in Italy, she said,
Genentech provided its medicines to more than 180,000 people last year for free or reduced cost. Willson noted that the Genentech Access to Care Foundation recently changed its financial criteria with the goal of helping more people, n recognition of the changing healthcare environment and the increasing number of people with high out
-of-pocket costs. The cancer drug placing lowest on the list of top sellers was Novartisgleevec (imatinib mesylate,#15),
In a statement to GEN, Novartis said it is looking into linking payment to patient outcomes
Novartis said. he majority of CML patients in the U s. pay less than $100 out of pocket per month for our CML treatments,
To that end, Novartis said, its patient assistance program provides the company medicines for free or at a reduced cost to those who can afford them,
000 uninsured or underinsured patients in the U s. annually for the past six-and-a-half yearsore than $1 billion in free medicine. ecause the cost of drugs is one of the few transparent healthcare costs,
drugs get much public attention, yet are only a small percentage of spending and demonstrate remarkable rewards,
Novartis asserted. reater attention should be paid to larger issues such as different charges for similar hospital services, costs across the complex healthcare systems and the growing complexity of our public and private
such rules may require treatment with a cheaper drug whose patent protection will expire soon,
The scientists believe their research paves the way to an entirely new approach for finding a drug that can cure
the only approved medication, extends the patient's life by a few months. More than a dozen genes are related to ALS.
This makes the TIR-1 protein (or SARM1 in humans) an excellent therapeutic target for development of a medication.
which can be blocked by existing drugs. Dr. Parker's team is already testing drugs that have been approved previously by the FDA for treatment of such disorders as rheumatoid arthritis
to see if they work with ALS. Obstacles still remain, however, before finding a remedy for curing
if a potential medication will prove effective if it is given only after appearance of symptoms.
the drug-treated mice showed a six-day-faster reconstitution of hematopoiesis after bone marrow transplantation. tudying mouse models,
The new technique holds the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens, according to the team.
and antibiotic resistance. The research team employed the Pacbio RS II system, which can collect data on base modifications simultaneously as it collects DNA sequence data.
assistant professor of genetics and genomics at the Icahn School of medicine at Mount sinai and senior author of the study. iven that phenotypic heterogeneity within a bacterial population can increase its advantage of survival under stress conditions such as antibiotic treatment,
This may have contributed to the increasing rate of antibiotic resistance of H. pylori. he application of this new technique will enable a more comprehensive characterization of the functions of DNA methylation and their impact on bacterial physiology.
such as RNA and protein expression, will help resolve regulatory relationships that govern higher order phenotypes such as drug resistance,
insight into the molecular basis of cocaine addiction.""Addiction is a lifelong affliction manifested by episodes of relapse,
"There is a need to more fully understand the long-term molecular changes in the brain involved in drug craving and relapse."
"Dr. Gancarz, a former postdoctoral associate with the UB Research Institute on Addictions (RIA), worked on the study under the direction of senior author David Dietz, Ph d.,assistant professor in the department of pharmacology
"There are changes in the brain caused by drug use that occur and persist, but are unmasked only after withdrawal from a drugn this case, cocaine,"notes Dr. Dietz."
and gene therapies to prevent drug relapses, "explains Dr. Dietz.""If we can control this pathway,
Implications for nsp5 regulation and the development of antivirals, June 8 in the Journal of Biological Chemistry.
which provides the map to design potent new drugs to fight MERS, "said Dr. Mesecar,
#New Drug Prevents Cancer cells from Staging Last Stand Unlike many last stands in human history,
one that would include a new drug, a small molecule called SBI-0206965 that inhibits autophagy.
The new drug targets ULK1, an enzyme that initiates autophagy. The drug, which was developed by scientists at Salk Institute
and Sanford Burnham Prebys Medical Discovery Institute (SBP), was described June 25 in Molecular Cell, in an article entitled, mall Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1
"This allowed us to find a drug that targeted ULK1 not just in a test tube but also in tumor cells.
Our work provides the basis for a novel drug that will treat resistant cancer by cutting off a main tumor cell survival process. i
Moreover, the rate of resistance to current drug therapies is growing exponentially and scientists are always on the hunt for novel targets that have the potential to not only treat symptoms of infected patients,
"As drug resistance is a major problem for malaria control and eradication, it is critical that that we continue to develop new antimalarials that act against previously unexploited targets in the parasite to keep priming the drug pipeline."
"The findings from this study were published recently in Cell Host Microbe through an article entitled"Parasite Calcineurin Regulates Host Cell Recognition and Attachment by Apicomplexans."
"In addition to a possible drug target, calcineurin underlies a very basic aspect of parasite biology. l
and in human tumor cells in the lab, showed that a specific drug can stop cancer cells without causing damage to healthy cells or leading to other severe side effects.
Thomas Burris, Ph d.,chair of pharmacology and physiology at SLU and colleagues at the Scripps Research Institute developed the novel therapeutic.
which started as an anti-cholesterol drug candidate, turns down fat synthesis so that cells can't produce their own fat.
The drug also has a good safety profile; it is effective without causing weight loss, liver toxicity,
The challenge for researchers in this scenario will be to find a way to allow the drug to cross this barrier, the body's natural protection for the brain,
drugs that modify LSD1 levels could provide a new approach to treating glioblastoma, according to the researchers.
"For instance, glioblastomas can escape the killing effects of a drug targeting MYC by simply shutting it off epigenetically
and turning it on after the drug is no longer present. Ultimately, strategies addressing this dynamic interplay will be needed for effective glioblastoma therapy."
and whether drugs could be developed to stop it from happening
#Sperm RNA Test May Improve Evaluation of Male Infertility Many couples who struggle with infertility also suffer uncertainty.
The team study (tructural basis for recognition of diverse transcriptional repressors by the TOPLESS family of corepressors appears in Science Advances."
Since the first biopharmaceutical drug Humulin was launched in 1982 to the beginning of this decade (between 1982 and 2009 27 year period),
It will be maintained as the source of all cells used to produce the company drug through preclinical and clinical testing and then into commercial sale.
2012, the U s. Food and Drug Administration approved the use of Flucelvax, which is the first U s.-licensed (trivalent inactivated) influenza vaccine manufactured using cell culture technology.
The engineered ribosome may enable the production of new drugs and next-generation biomaterials and lead to a better understanding of how ribosomes function, according to the researchers.
The artificial ribosome, called Ribo-T, was created in the laboratories of Alexander Mankin, Ph d.,director of the UIC College of Pharmacy's Center for Biomolecular Sciences
#Merck-Newlink Genetics Ebola Vaccine Shows 100%Efficacy in Phase III Trial Merck & co. and Newlink Genetics said today that a single dose of their Ebola vaccine candidate rvsv
The hope is that this could lessen the side effects of pain relief drugs.""You don want to feel sleepy or unaware,
and required technology to actually test different drugs to find something that targets the peripheral nervous system and not the central nervous system in a patient specific, or personalized manner."
000 units and manufactures mainly three different size units to be sold on a wholesale basis. However,
This step was all-important as it prevents the drug from replicating with normal healthy cells
Around 16 percent of those given T-VEC demonstrated durable responses of more than six months, compared to just over two percent of those given the control drug.
The researchers found the drug to be most effective when used in the less advanced stages of the cancer, suggesting that T-VEC could prove a valuable early treatment option for skin cancers that are unable to be removed by a surgeon.
The drug has been submitted to both the US Federal Drug and Food administration and the European Medicines Agency for consideration, with the scientists hopeful of winning approval later this year.
The reason why this still happens on a daily basis is that not every task lends itself to automation.
#Student-designed pill dispenser uses fingerprint scanner to avoid overdosing And you thought that regular pill bottles were hard to open...
a new overdose-proof medication dispenser developed by a team of mechanical engineering students at Johns hopkins university can't be opened even with the help of a hammer or drill.
Many people exceed the recommended dosage of such pharmaceuticals, risking both their immediate health and the chance of developing a long-term addiction.
In the case of the Johns Hopkins dispenser, medication is added by the pharmacist via a lockable opening in the bottom the pharmacist has a key to that opening,
When they're subsequently supposed to take a pill, the patient holds their finger pad to the dispenser's scanner.
picking up a pill from a loaded cartridge and dropping it into an exit channel.
the treatment doesn't carry the risk of side effects that are associated often with drug treatments."
These body parts are prone to absorbing certain medications before they can do their best work.
The material could also form the basis of the basis for a new family of highly energy-efficient near-infrared LEDS,
It also houses four separate chambers for carrying drugs directly to the brain and cellular-scale inorganic light-emitting diode(-ILED) arrays, allowing it to shine light on targeted cells.
If we want to influence an animal behavior with light or with a particular drug, we can simply point the remote at the animal and press a button."
the researchers were able to negate this action by remotely releasing a drug that blocks the function of the dopamine neurotransmitter.
so that drugs can be drip-fed to targeted cells as needed over a long time.""Wee successfully produced
#Pill on a string pulls early signs of cancer As with every form of the deadly disease,
what they claim to be a more accurate tool for early-diagnosis. Billed as"a pill on a string,
The Cytosponge is around the same size as a multi vitamin pill but instead of nutrition it packs a tightly compressed sponge.
the implant received market approval from the Food and Drug Administration (FDA) in the US, for the treatment of Retinitis Pigmentosa (RP) a degenerative condition that affects the peripheries of patient vision.
which is strong enough to stabilize various types of compounds, such as antibodies, enzymes, nanoparticles, antibiotics and growth factors, by acting as a protective"cocoon"."
the word changed from blue to red. a plastic dish imprinted with BMP-2 proteins that stimulate bone growth to control the direction of tissue growth. sodium ampicillin printed on a bacterial culture printed to test the effectiveness of a topographical distribution of the antibiotic
Omenetto says the ability to print antibiotics in topographical patterns would enable"smart"bandages in
the researchers gave the men a drug called buspirone during the final four weeks of the 18-week study.
This drug mimics the neurotransmitter serotonin and it is known to induce walking motions in mice with spinal cord injuries.
But by the end of the study, after they had received the buspirone drug, they could all move their legs with no stimulation at all.
Drugs already exist that can deactivate those cells. They are known as calcilytics and are used to treat people with osteoporosis. Researchers found that,
when the drug is inhaled, it deactivates the cells and stops all symptoms. Go ahead and Let Dogs Lick You,
Scientists are hopeful that patients can take the drug to prevent asthma attacks before they start ending the need to constantly carry an inhaler to end symptoms once an attack has started.
Glaxosmithkline Vice president for Africa told CNN. t is the first time anyone ever has been able to make a vaccine against a parasite.
Perhaps most impressive, Glaxosmithkline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS, S available as a nonprofit drug.
It will be offered at a low cost to cover manufacturing costs plus a 5%markup with all that money going back into further research for a malaria vaccine that could be even more effective.
encourage the utilities to do exactly that--take risks, on a portfolio basis, at reasonable volumes, this year e
#Harvard Organic Flow battery Under Development in Europe Last year, the Harvard School of engineering and Applied sciences demonstrated a flow battery concept in the laboratory that used organic quinone molecules as the basis for its electrolyte.
announced recently that five million medications have been tracked using radio frequency identification technology. Adam Buckley, MD, interim chief information officer and chief medical informatics officer at UVMC, said any time a system allows a hospital to track reliably from ordering through dispensing through administration at the bedside,
"It's cutting down on medication errors, ensuring that medications are given in a timely fashion,
and it's a great way to leverage technology and systems to help address human factor issues,
A vial of the drug Glycopyrrolate with a strength of 1mg/ML became the five-millionth RFID-tagged dose at UVMC tracked by Kit Check, a Washington, D c,
.-based company that makes automated hospital pharmacy kit processing and medication tracking software. Karen Mcbride, UVMC's director of pharmacy services, said that patient safety was the main reason for utilizing RFID technology."
"We use a lot of kits in this hospital because our ORS are set up to have dispensed individual kits to the anesthesiologist for each case,
"she said.""We have hundreds of kits in addition we have kit-like trays in our code blue carts and on our resuscitation carts."
there's always a concern around putting the wrong medication accidentally in a kit and that the RFID kit technology essentially eliminates that possibility.
as the pharmacy receives drugs that are going to be going into these kits pharmacy technicians put into the software system
what the drug is, the quantity, the lot number and the expiration date. Then they print out the RIFD tag from that information and label the drugs with it."
"There's an independent double-check where a second person goes in and puts in the information to help prevent an error
-based expert and consultant on bar code-enabled medication dispensing, preparation and administration, said Kitcheck"has succeeded out of the gate"by applying RFID tags to anesthesia kits, already operational in over 100 hospitals.
what they refer to"critical inventory"used by hospitals high-cost medications in refrigerators and high-risk drugs in anesthesia kits and trays.
when administering medications, a nurse could know via proximity reading that he or she has five medications in his hand,
one of which is not due for his patient. According to Neuenschwander, the nurse would then need to move all five items out of the range of read
if RFID chips will ever displace barcodes on drug packages any more than on cereal boxes in grocery stores.
grams/kilograms and liters/milliliters in pharmacy, for example. But miles, feet and inches, pints, quarts,
Other focus points include staying ahead of drug-resistant bacteria, finding cures to Alzheimer and other diseases, developing new clean energy technologies,
#Delivering drugs straight into the brain A team of Canadian scientists has found a way to inject the drugs directly into the brain,
such as disease fighting drugs from entering the nervous system. It only allows a selected few types of molecules to cross including water, some gases and lipid soluble molecules.
and get the drugs to where they are needed most to the human brain. Currently, researchers say they have found a way based on the so-called ingle domain antibodiessda.
The discovery follows years of scientific Work at the moment drugs are placed usually into the blood
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011